Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: SOLICH
Liczba odnalezionych rekordów: 2



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku

1/2

Tytuł oryginału: Effect of repeated treatment with reboxetine on the central ŕ1-adrenergic and dopaminergic receptors.
Autorzy: Rogóż Zofia, Margas Wojciech, Skuza Grażyna, Solich Joanna, Kuśmider Maciej, Dziedzicka-Wasylewska Marta
Źródło: Pol. J. Pharmacol. 2002: 54 (6) s.593-603, il., tab., bibliogr. 48 poz.
Sygnatura GBL: 313,156

Hasła klasyfikacyjne GBL:
  • farmacja

    Typ dokumentu:
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta
  • szczury
  • płeć męska

    Streszczenie angielskie: Reboxetine (REB) is a member of a new class of antidepressants drugs, which selectively inhibit the neuronal reuptake of noradrenaline. It is devoid of any affinity for neurotransmitter receptors nor does it inhibit monoamine oxidases A or B. Since our earlier studies have shown that antidepressant drugs administered repeatedly increase the responsiveness of ŕ1-adrenergic receptors and induce the up-regulation of postsynaptic dopamine D2/D3 receptors in the rat brain, we designed the present experiments to determine whether repeated administration of REB evokes similar effects. The experiments were carried out on male Wistar rats. REB was administered at a dose of 10 mg/kg (or 30 mg/kg in some cases) once or repeatedly (twice daily for 14 days). The obtained results show that REB administered repeatedly increased exploratory behavior induced by phenylephrine and potentiated the hyperlocomotion induced by D-amphetamine. These behavioral effects indicate the hyperresponsiveness of 1-adrenergic receptors. Biochemical studies did not show any changes in the binding parameters of [3H]prazosin (Bmax or Kd), but the ability of the ŕ1-adrenergic receptor agonist, phenylephrine, to complete for these sites was significantly increased upon repeated administration of REB. Locomotor activity induced by quinpirole was not changed, although there was a potentiation of 7-OH-DPAT-induced locomotor hypereactivity in rats receiving repeated administration of REB. At the same time no significant changes in the binding of [3H]quinpirole and [3H]7-OH-DPAT, or at the level of mRNA...


    2/2

    Tytuł oryginału: Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression.
    Autorzy: Dziedzicka-Wasylewska Marta, Rogóż Zofia, Solich Joanna, Dudek Dominika, Wróbel Andrzej, Zięba Andrzej
    Źródło: Pol. J. Pharmacol. 2002: 54 (6) s.703-706, il., bibliogr. 13 poz.
    Sygnatura GBL: 313,156

    Hasła klasyfikacyjne GBL:
  • psychiatria i psychologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: Treatment of the patients suffering from therapy-resistant unipolar depression with joint administration of imipramine (twice daily, 100-150 mg/day) an amantadine (twice daily, 150 mg/day) for four to six weeks resulted in the significant increase in the binding of [3H]17-OH-DPAT to dopamine D3 receptors in the peripheral blood lymphocytes. This effect correlated well with the clinical improvement, estimated with Hamilton's Depression Rating Scale. In the light of the above data, it seems justified to postulate that joint therapy with imipramine and amantadine may be successful in the treatment-resistant unipolar depression.

    stosując format: